The FDA agrees that results from Biogen’s late-stage trial, study 302, are “highly persuasive” and the study is “capable of providing the primary contribution to a demonstration of substantial evidence of effectiveness of aducanumab.” Source

JOIN NCOV.LINK NEWSLETTER

And get notified everytime we publish a new Important announcements. We will not email you often, unless there are important things that need to get in touch with you, such as added new tools or new domain names.